title: A patient with cancer and nail pigmentation.
authors.affiliation: Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA abhishek.maiti@uth.tmc.edu.
authors.forename: Abhishek
authors.initials: A
authors.lastname: Maiti
authors.affiliation: Department of Cardiology, Pacific Cardiology Associates, Fremont, CA, USA.
authors.forename: Sreyasi
authors.initials: S
authors.lastname: Bhattacharya
mesh_terms: D000328:Adult; D001741:Black or African American; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D064147:Febrile Neutropenia / Q000139:chemically induced; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy*; D009260:Nail Diseases / Q000139:chemically induced*; D009262:Nails / Q000187:drug effects* / Q000473:pathology*; D010859:Pigmentation Disorders / Q000139:chemically induced*; D011241:Prednisone / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000009:adverse effects
chemical_list: D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone